La proteína S-100 como marcador tumoral en pacientes con melanoma cutáneo

Sevila Llinares, Amparo; Ortiz Muñoz, Blanca ; Botella Estrada, Rafael; Sanmartín Jiménez, Onofre; Maiquez Richart, Joaquín; Guillén Barona, Carlos.
Actas dermo-sifiliogr. (Ed. impr.) ; 91(9): 379-384, sept. 2000. graf
Artículo en Es | IBECS (España) | ID: ibc-3959

Documentos relacionados

  1. S100 protein measurement in clinical practice.
  2. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline.
  3. Primary colonic melanoma: a rare entity.
  4. Primary gallbladder melanoma: A systematic review of literature.
  5. [Malignant gastrointestinal neuroectodermal tumor: a clinicopathological analysis of three cases].
  6. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.
  7. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis.
  8. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
  9. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
  10. New serum tumor markers S100, TFF3 and AIF-1 and their possible use in oncogynecology.